Kristen Coppock, MA, Editor

In a satellite symposium at the 2018 American Society of Health-Systems Pharmacists (ASHP) Midyear Clinical Meeting in Anaheim, CA, the increasing rate of drug shortages was discussed, along with best practices pharmacists can use to mitigate the ongoing issue.

Rural areas are prone to unique health care challenges that are being met with policy changes and innovation.

The drug’s application was designated for fast track and priority review, as well as orphan product status.

The FDA has expanded the approved use of Seattle Genetics’ Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.

The FDA has expanded the approved use of Seattle Genetics’ Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL).

Findings showed that LAIV was more effective in those vaccinated in both the enrollment season and the prior season than in those vaccinated only in the enrollment season.

This cannabidiol oral solution can be prescribed in the United States to treat seizures associated with Dravet or Lennox-Gastaut syndrome.

Officials with the FDA have approved Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy. The drug is a biosimilar to Amgen’s Neulasta (pegfilgrastim).

Officials with the FDA have approved Coherus BioSciences’ Udenyca™ (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy. The drug is a biosimilar to Amgen’s Neulasta (pegfilgrastim).

Drug manufacturers, patient advocates, and professional organizations are giving a big thumbs-up to the SUPPORT for Patients and Communities Act.

Breckenridge Pharmaceutical's Clobazam Tablets, CIV, generic for Onfi® Tablets (Lundbeck), has been granted FDA approval for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older.

The FDA will address new ways to increase the availability of naloxone, during a 2-day advisory committee meeting in December.

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older.

The FDA has approved dupilumab (Dupixent®, Regeneron and Sanofi) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

A pair of pivotal Phase 3 placebo-controlled trials that evaluated dupilumab (Dupixent, Sanofi and Regeneron) for adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all primary and secondary endpoints.

A new program available through the American Society of Health-System Pharmacists is 1 of multiple Pharmacogenomics Certificate courses available to pharmacists.

On Wednesday, during a live webcast from the White House, President Trump signed into law a pair of bipartisan bills that has made 'gag clauses' in contracts an illegal practice.

Insurers and pharmacy benefit managers can no longer restrict pharmacies from providing drug price information to customers.

President Trump signed into law a pair of bipartisan bills that has made 'gag clauses' in contracts an illegal practice.

The FDA has approved Akcea Therapeutics' inotersen (Tegsedi), an antisense oligonucleotide that inhibits the production of the transthyretin protein (amyloid), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

FDA officials have approved omadacycline (Nuzyra, Paratek), a modernized tetracycline, to treat adults with acute skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

The FDA has approved sarecycline (Seysara, Almirall) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.

Epidiolex was approved to treat seizures associated with 2 rare and severe forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome—in patients aged 2 years and older.

The American Society of Health-System Pharmacists (ASHP) has published guidelines with practical recommendations and best practices for preventing patient harm from medication errors.

The Drug Enforcement Administration is placing Epidiolex in Schedule V, the least restrictive of the Controlled Substances Act

Officials with the FDA have approved Admais’ 0.15mg Symjepi for the emergency treatment of allergic reactions, including anaphylaxis, in children.

A global survey found that 2 of 3 individuals with type 2 diabetes had experienced a cardiovascular disease (CVD) event or had CVD risk factors.